0.50p
(2.50%)
Add to watchlist
Create an alert
Stocks and Shares ISASareum Holdings plc is a United Kingdom-based clinical-stage biotechnology company. The principal activity of the Company is the discovery and development of new therapeutic drugs using a combination of skills in biology, computational chemistry and medicinal chemistry. The Company is focused on advancing inhibitors of the JAK kinase family into clinical development for autoimmune disease and cancer. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, including psoriasis, and has completed Phase 1 clinical development. The Company is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy. Additionally, the Company owns the license for SRA737, a clinical-stage oral, selective Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms.
Company Information
About this company
Key people
Stephen Barry Parker
Executive Chairman of the Board
John C. Reader
Founder, Chief Scientific Officer, Executive Director
Tim J. Mitchell
Chief Operating Officer - Part Time, Executive Director
Michael John Owen
Non-Executive Director
Clive H.W. Birch
Senior Non-Executive Independent Director, Secretary
Click to see more
Key facts
- Shares in issue138.07m
- EPICSAR
- ISINGB00BMC3RJ87
- LocationUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap£26.92m
- Employees5
- ExchangeLondon Stock Exchange (LON)
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.